COMMON MAPS
Map version new-york activity top-down
Main site Contact
Menu
↑ parent activity group ·
research dossier

TARGET ALS FOUNDATION INC
NEW YORK, NY · EIN 810756743 · Form 990 · FY2025 · NTEE B82 · Education · Large ($10M-$50M) · targetals.org
revenue
$33.3M
expenses
$25.6M
net assets
$135.1M
employees
18
volunteers
36
program ratio
82%
mission · from form 990

OUR MISSION IS TO BREAK DOWN BARRIERS TO ALS RESEARCH TO FIND EFFECTIVE TREATMENTS. BY UNITING ACADEMIA, THE PHARMA AND BIOTECH INDUSTRY, GOVERNMENT, VENTURE CAPITAL, RELATED NONPROFITS, AND THE ALS COMMUNITY, WE AIM TO OVERCOME THE CHALLENGES THAT HAVE LONG HINDERED PROGRESS, BRINGING HOPE AND TANGIBLE ADVANCEMENTS TO THOSE AFFECTED BY THIS DEVASTATING DISEASE.

profile · synthesized from sources

Target ALS Foundation is a nonprofit accelerating research to find effective treatments for amyotrophic lateral sclerosis (ALS). By uniting academia, industry, government, and the ALS community, it funds, enables, and conducts research through an open-access Innovation Ecosystem. The organization emphasizes radical collaboration, removing barriers like intellectual property restrictions and funding bias to speed scientific discovery.

named programs · 4 · from sources

What they call their work

ALS Global Research Initiative (AGRI)
The largest and most inclusive global ALS study, including the Global Natural History Study and Community-Based Pop-Up Clinics, designed to expand diversity in ALS research and accelerate biomarker discovery.
Data Engine
A first-of-its-kind platform offering free, unrestricted access to multi-omic ALS data linked to real biosamples, developed in partnership with DNAstack and Verily.
Innovation Ecosystem
A model that funds collaborative research, provides open access to data and tools, and fosters partnerships between academia and industry to accelerate ALS breakthroughs.
Research Cores
Open-access repositories providing researchers worldwide with biospecimens, genomic datasets, and stem cell lines without intellectual property restrictions.
activities · 5 groups

What they do

  • Scientific Conference & Symposium Management 2 activities
    • Convening of global ALS research community
      Hosts annual meetings bringing together over 1,200 participants from 35+ countries, including researchers, clinicians, industry representatives, and patient advocates. The meetings facilitate presentation and peer feedback on unpublished research, feature over 80 speakers, and publish reports summarizing scientific advances and collaborations. Events are held both in-person and virtually, with recent meetings in 2025 and 2026.
    • Facilitation of cross-sector collaboration and innovation
      Sponsors targeted discussions and roundtables on emerging topics such as AI in drug discovery, with participation from major industry players including Roche, Lilly Ventures, and insitro, to foster innovation and collaboration across sectors.
  • Biomedical Research and Innovation 2 activities
    • Facilitation of drug discovery and clinical translation
      58% of funded research consortia have advanced to drug discovery programs. Supported the development of 13 clinical trials through funded research projects, translating laboratory findings into viable treatment pathways.
    • Open data sharing and research infrastructure
      Generates and freely shares rich clinical and multi-omic datasets through its online Data Engine, enabling global research access. Ensures data from studies like the Global Natural History Study are immediately available to researchers worldwide.
  • Alzheimer's Research and Support Services 1 activity
    • Funding and management of ALS research grants
      Funds over 750 research grants in ALS research, investing more than $80 million, including $59.3 million allocated to 78 consortia. Allocates funding across key areas: 41% to understanding ALS biology and therapeutic targets, 25% to drug discovery, and 33% to biomarker development. Issues targeted funding opportunities for ALS biomarkers and in vivo target validation.
  • Open Research Infrastructure & Publishing 1 activity
    • Provision of unrestricted research tools and resources
      Provides scientists worldwide with no-strings-attached, expedited access to high-quality, standardized research tools, data, and expertise. Supports over 1,950 scientific partners globally with resources including data, models, antibodies, and technical support.
  • Uncategorized 2 activities
    • Development and maintenance of ALS research resources and biorepositories
      Maintains a global biorepository with over 50,000 vials of biofluid samples (CSF, blood, urine), postmortem tissues from over 500 ALS cases, and induced pluripotent stem cell (iPSC) lines. Generates multi-omic data (whole-genome sequencing, RNA-seq, proteomics) linked to clinical records. Provides validated antibodies and ALS animal models with unrestricted access for researchers worldwide.
    • Operation of global ALS research initiatives and clinical studies
      Conducts research through 15 active global sites as part of the ALS Global Research Initiative (AGRI), enrolling 350 participants including individuals with ALS and healthy controls. Operates the Global Natural History Study, which provides immediate access to participant data and samples. Prioritizes diversity, with 36% non-Caucasian enrollment in this study and broader efforts to include greater ethnic, genetic, and geographic representation.
financials · form 990 · fy2025
revenue
Total revenue$33.26M
Contributions & grants$29.72M89%
Program service revenue$00%
Investment income$3.54M11%
Other revenue$2K
expenses
Total expenses$25.62M
Program expenses82%
Admin / overhead11%
Fundraising7%
Salaries & benefits$3.86M
Grants paid out$18.77M
Largest expense lineCompensation
balance sheet
Total assets$136.91M
Cash$7.96M
Investments$83.18M
Liabilities$1.85M
Net assets$135.06M
Liquid reserves42.7 mo
7 years on record · 2019–2025 · YoY revenue -35.7%
leadership · form 990 part vii · fy2025

Who runs it

paid leadership · 8
NameTitleHours/wkCompensation
MANISH RAISINGHANI PRESIDENT 40 $445K
AMY EASTON VICE PRESIDENT, RESEARCH GROUPS 40 $369K
KENNETH DEVANEY CHIEF OPERATING OFFICER 40 $329K
JESSICA CHAPMAN CHIEF DEVELOPMENT OFFICER 40 $309K
YULIYA RZAD CHIEF GRANTS OFFICER 40 $250K
CHRISTINE PROUTY ARANYOS DIRECTOR OF PHILANTHROPY 40 $227K
LAURA DUGOM ASSOCIATE DIRECTOR CLINICAL RESEARCH 40 $198K
STEPHANIE ISHOO DIRECTOR OF MARKETING & COMMUNICATIONS 40 $193K
board members · 14
  • ALISA DOCTOROFF — BOARD MEMBER
  • ALLISON JAFFIN — BOARD MEMBER
  • ANDY BERNDT — BOARD MEMBER
  • BRAD S KARP — BOARD MEMBER
  • CAROL HO — BOARD MEMBER
  • CHRIS HERNDERSON — BOARD MEMBER
  • DANIEL L DOCTOROFF — BOARD CHAIR
  • ERIC DANE — BOARD MEMBER (AS OF 12/25)
  • JOHN DUNLOP — BOARD MEMBER
  • RICHARD HARGREAVES — BOARD MEMBER
  • SARAH SHEIKH — BOARD MEMBER
  • STACY WENINGER — BOARD MEMBER
  • STORY LANDIS — BOARD MEMBER
  • ZACH W HALL — BOARD MEMBER
relationships · 20

Who they work with

  • ALS Global Research Initiative (AGRI) Partner — Collaborative research initiative focused on enrolling diverse participants to advance understanding of ALS.
  • Alisa Doctoroff Partner — Board Member and founding donor of Target ALS who delivered opening remarks at the 2026 Annual Meeting.
  • Biospective Partner — Contract research organization partnered with to evaluate novel therapeutics for target engagement and disease-modifying potential in ALS mouse models.
  • Community-Based Pop-Up Clinics Partner — Local partner clinics and one-day events that facilitate biofluid sampling in underrepresented communities.
  • DNAstack Partner — Collaborated with Target ALS to build the Data Engine research core for open ALS data access.
  • Dan Doctoroff Partner — Founder and Chairman of Target ALS who delivered opening remarks at the 2026 Annual Meeting.
  • Dan Doctoroff Partner — Founder of Target ALS, former NYC Deputy Mayor, and person living with ALS.
  • Dr. Amy Easton Partner — Senior Director of Scientific Programs at Target ALS who co-hosted a webinar following the 2025 Annual Meeting.
  • Dr. Manish Raisinghani Partner — CEO of Target ALS who participated in a post-meeting webinar discussing the organization's mission and research challenges.
  • Global Natural History Study Partner — Core research study under AGRI that collects and distributes global ALS data and biosamples.
  • Lilly Ventures Partner — Collaborated with through sponsorship of a roundtable discussion on AI in drug discovery at the Annual Meeting.
  • Roche Partner — Collaborated with through sponsorship of a roundtable discussion on AI in drug discovery at the Annual Meeting.
  • Sampled Partner — Partner organization responsible for storing and managing the Stem Cell Core's iPSC lines.
  • Springboard Fellows Partner — Early-career researchers supported through Target ALS fellowships
  • Target ALS Annual Meeting Network — Forum where researchers and stakeholders convene to share progress and advance collaborative ALS research.
  • Verily Partner — Collaborated with Target ALS to build the Data Engine research core for open ALS data access.
  • academic institutions Partner — Engages academic institutions globally in ALS research through collaborative scientific meetings and data-sharing initiatives.
  • insitro Partner — Collaborated with through sponsorship of a roundtable discussion on AI in drug discovery at the Annual Meeting.
  • nonprofit organizations working on ALS Partner — Partners with nonprofit organizations focused on ALS and related neurodegenerative diseases to advance research and treatment development.
  • pharma/biotech firms Partner — Collaborates with pharma/biotech firms in ALS research and drug development through convenings and shared scientific initiatives.
strategies · 5

How they approach the work

Named approaches extracted from this org’s sources. Where others share an approach, follow it to see the full set of orgs running it.

  • Collaborative Research Acceleration
    methodology: collaborative_research_acceleration
    By uniting academic, industry, and cross-disciplinary scientists in funded consortia and global networks, we accelerate ALS discovery because breaking down silos fosters innovation, reduces duplication, and speeds translation of findings into treatments.
  • Data-Driven Target Discovery
    methodology: data-driven_target_discovery
    By curating high-quality, diverse clinical and multi-omic datasets linked to biosamples, we enable effective AI modeling for target discovery and patient stratification because robust, real-world data is foundational to identifying viable therapeutic pathways.
  • Equitable and Inclusive Research Participation
    methodology: community-engaged_research
    By engaging underrepresented populations through community-based clinics and global outreach, we build more representative datasets because inclusivity improves scientific validity and ensures treatments benefit all patient subgroups.
  • Investment in Emerging Scientific Talent
    methodology: emerging_talent_investment
    By funding early-career researchers with bold ideas, we strengthen the ALS innovation pipeline because nurturing new voices introduces fresh perspectives and ensures long-term momentum in the field.
  • Open-Science Collaboration Model
    methodology: open_science_infrastructure
    By providing open access to standardized, high-quality research resources—including data, biospecimens, and tools—we accelerate ALS breakthroughs because it removes historical barriers of cost, quality, and access, enabling global scientists to build on shared knowledge without duplication or delay.